Gain Therapeutics, Inc. GANX
1.08 USD -0.03 (-2.70%)
At closeNov 13, 2026, 7:35 AM EST
1.12 +0.04 +3.70%
Pre-market · Nov 13, 7:35 AM ET
1.01 Day range 1.14
0.94 52-week range 4.34
- YTD
- -66.46%
- 1 year
- -63.39%
News
benzinga.com Gain Therapeutics Q3 EPS $(0.07) Beats $(0.12) Estimate Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.12) by 41.67 percent. This is a 53.33 percent increase over losses of…
globenewswire.com Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update BETHESDA, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the…
benzinga.com HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.
benzinga.com Gain Therapeutics Announces Poster Presentation At International Congress Of Parkinson’s Disease And Movement Disorders, October 4-8; MDS-UPDRS Motor Scores Demonstrated Stability To Baseline Recorded At Study Entry With No Disease Progression Among The 12 Evaluable Participants; Results Support Disease-Modifying Potential Of Rexaceract Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule- benzinga.com Gain Therapeutics Reveals Poster Presentation At International Congress Of Parkinson’s Disease and Movement Disorders Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule
- benzinga.com HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.
- benzinga.com Gain Therapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 42.11 percent increase over losses of…
benzinga.com Gain Therapeutics Issues CEO Letter; Expects To Fund Operations Into Q2 2027, Based On Current Operating Plans, Including Completion Of Phase 1B Open-Label Extension In October And Initiation Of A Phase 2 During Q3 2026 To our valued Shareholders,As we progress through 2026 and look ahead to delivering continued significant progress, I want to thank you for your steadfast support of Gain Therapeutics. The year has…
benzinga.com HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market session. The market value of their outstanding shares is at $74.6 million. BNB Plus (NASDAQ:BNBX) stock…- benzinga.com Gain Therapeutics Obtains FDA Clearance Of IND To Advance GT-02287 Into Phase 2 Clinical Development for Parkinson’s Disease; IND Authorization Paves The Way For Initiation Of GT-02287 Phase 2 Clinical Development In The U.S., Expected During Q3'26 IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26FDA’s decision follows positive Phase 1 results for GT-02287 in both healthy…
- benzinga.com Gain Therapeutics To Give Oral Presentation Update On GCase Modulator For Parkinson's Disease At 3rd International GBAI Meeting May 22-23 Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant…
benzinga.com Gain Therapeutics Q4 EPS $(0.11) Beats $(0.17) Estimate. Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 35.29 percent. This is unchanged from the same period last year.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Gain Therapeutics Presents Poster At AD/PD 2026 International Conference on Alzheimer's And Parkinson's Disease And Related Neurological Disorders On New Clinical, Biomarket Data From Phase 1B Clinical Trial Of GT-02287 Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Gain Therapeutics Reports Early Parkinson's Trial Results, Drug Cuts Disease Marker by 81% in Early Gain Therapeutics Study Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule…
benzinga.com Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - benzinga.com HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com Gain Therapeutics Reports Early Parkinson's Study Showing Brain Biomarker Improvement After 90 Days Of Treatment Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule…
benzinga.com Gain Therapeutics Q3 EPS $(0.15) Beats $(0.16) Estimate Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 7.41 percent. This is a 11.76 percent increase over losses of…- benzinga.com HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.
benzinga.com Maxim Group Maintains Buy on Gain Therapeutics, Raises Price Target to $7 Maxim Group analyst Jason McCarthy maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and raises the price target from $5 to $7.- benzinga.com Gain Therapeutics Presents Phase 1b GT-02287 Data At International Congress Of Parkinson's Disease And Movement Disorders, Highlighting Safety, Tolerability, And Exploratory Findings In PD Patients With or Without GBA1 Mutation Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participantsPlasma exposures in patients within projected therapeutic range and…
- benzinga.com Gain Therapeutics Begins GT-02287 Phase 1b Extension Study Allowing Participants To Continue Treatment For Additional Nine Months Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing scheduleThe Phase 1b study enrolled 21…
- benzinga.com BTIG Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target BTIG analyst Thomas Shrader reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 price target.
- benzinga.com Roth Capital Maintains Buy on Gain Therapeutics, Lowers Price Target to $6 Roth Capital analyst Boobalan Pachaiyappan maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and lowers the price target from $7 to $6.
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus U.S. stock futures swung between gains and losses on Wednesday after ending on a mixed note on Tuesday. Futures of major benchmark indices were mixed.
benzinga.com Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of American Eagle Outfitters, Inc. (NYSE: AEO) declined during Tuesday’s session after the company reported third-quarter financial results. Net revenue rose 5% Y/Y to $1.30 billion, beating…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 540 companies set new 52-week lows.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2022 Upgrades
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's trading, 505 companies set new 52-week lows.
- benzinga.com 52 Biggest Movers From Yesterday Gainers ION Geophysical Corporation (NYSE: IO) shares surged 29.8% to settle at $0.5969.
- benzinga.com 34 Stocks Moving In Tuesday's Mid-Day Session Gainers Biofrontera Inc. (NASDAQ: BFRI) shares climbed 30.7% to $4.4095 after the company provided an update on patient recruitment for the Phase III study for the treatment of sBCC with Ameluz-PDT.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 445 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday morning, 207 companies hit new 52-week lows.